[12] Patent
[11] Patent No.:GC0004496  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2016                32/2016  
Number of the Decision to Grant the Patent:2016/88975
Date of the Decision to Grant the Patent:05/Dec/2016

[21] Application No.:GC 2010-15681

[22] Filing Date:17/4/2010

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
23/4/2009
61/172,039

[72] Inventors:1- HUGHES, Adam،2- BYUN, Daniel،3- CHEN, Yan،4- FLEURY, Melissa،5- JACOBSEN, John R،6- STANGELAND, Eric،7- WILSON, Richard D،8- YEN, Rose

[73] Owner: Theravance Respiratory Company, LLC, 901 Gateway Boulevard, CA 94080, South San Francisco, USA

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: C07D 40/12; A61k 31/444; A61P 11/00, 11/08 (2006.01)

[56] Cited Documents:

-US 7141671 B1 (MAMMEN MATHAI [US] ET AL) 28 November 2006
-US 2006/035931 A1 (CHAO ROBERT S(US ET AL) 16 February 2006
-WO 2007/090859 Al (GALAXO GROUP LTD [GB]; CHUDASAMA RESHMA (GB]; KENNEDY ANDREW [GB]; KIND)16 July 2007
-WO 2006/023454 Al (THERAVANCE INC [US]; CHAO ROBERT S [US], RAP f A MIROSLAV [US], COLOSON P) 2 March 2006
 
Examiner: PH. Nada A. AlShamrani

[54] DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND B2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
[57] Abstract: This invention relates to a compound of formula I:Ior a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and ?2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.
No. of claims: 12


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.